DE69124415T2 - Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen - Google Patents

Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen

Info

Publication number
DE69124415T2
DE69124415T2 DE69124415T DE69124415T DE69124415T2 DE 69124415 T2 DE69124415 T2 DE 69124415T2 DE 69124415 T DE69124415 T DE 69124415T DE 69124415 T DE69124415 T DE 69124415T DE 69124415 T2 DE69124415 T2 DE 69124415T2
Authority
DE
Germany
Prior art keywords
oxoprostaglandin
dehydroxy
treatment
allergic diseases
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69124415T
Other languages
English (en)
Other versions
DE69124415D1 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of DE69124415D1 publication Critical patent/DE69124415D1/de
Application granted granted Critical
Publication of DE69124415T2 publication Critical patent/DE69124415T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69124415T 1990-04-27 1991-04-24 Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen Expired - Lifetime DE69124415T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11230390 1990-04-27
JP6132791 1991-03-01

Publications (2)

Publication Number Publication Date
DE69124415D1 DE69124415D1 (de) 1997-03-13
DE69124415T2 true DE69124415T2 (de) 1997-05-15

Family

ID=26402368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124415T Expired - Lifetime DE69124415T2 (de) 1990-04-27 1991-04-24 Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen

Country Status (10)

Country Link
EP (1) EP0454429B1 (de)
JP (1) JPH07103030B2 (de)
KR (1) KR970005173B1 (de)
AT (1) ATE148344T1 (de)
AU (1) AU639322B2 (de)
CA (1) CA2041240C (de)
DE (1) DE69124415T2 (de)
DK (1) DK0454429T3 (de)
ES (1) ES2099736T3 (de)
GR (1) GR3022706T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149838T1 (de) * 1992-08-07 1997-03-15 Schering Ag Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CN103781482A (zh) * 2011-04-19 2014-05-07 苏坎波公司 用于调节细胞因子活性的方法
EP2701709A4 (de) * 2011-04-27 2014-10-15 Sucampo Ag Verfahren zur modulation von ionentransportern
JPWO2012176792A1 (ja) * 2011-06-21 2015-02-23 株式会社アールテック・ウエノ 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物
US20160228403A1 (en) * 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644638A (en) * 1970-08-24 1972-02-22 American Home Prod Compositions and methods for relieving bronchial spasm with prostanoic acids and esters
US3836667A (en) * 1972-03-24 1974-09-17 Miles Lab Method of producing bronchodilation
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
EP0153858A3 (de) * 1984-02-29 1985-12-11 The Upjohn Company Therapeutische Anwendung von Protaglandinen
US4879285A (en) * 1986-08-22 1989-11-07 Royal North Shore Hospital And Area Health Service Fertility control
AU616502B2 (en) * 1988-04-22 1991-10-31 Medvet Science Pty. Ltd. Treatment of inflammatory disorders in humans
ATE135207T1 (de) * 1989-04-04 1996-03-15 Beiersdorf Ag Mittel zur atopieprophylaxe
EP0444844B1 (de) * 1990-02-26 1995-01-18 R-Tech Ueno Ltd. 15-Dehydroxy-16-oxoprostaglandine

Also Published As

Publication number Publication date
CA2041240A1 (en) 1991-10-28
DE69124415D1 (de) 1997-03-13
EP0454429A2 (de) 1991-10-30
JPH04330015A (ja) 1992-11-18
CA2041240C (en) 2001-07-31
ATE148344T1 (de) 1997-02-15
GR3022706T3 (en) 1997-05-31
KR910018028A (ko) 1991-11-30
EP0454429B1 (de) 1997-01-29
KR970005173B1 (ko) 1997-04-14
ES2099736T3 (es) 1997-06-01
EP0454429A3 (en) 1992-07-15
DK0454429T3 (da) 1997-03-17
AU7593091A (en) 1991-11-07
AU639322B2 (en) 1993-07-22
JPH07103030B2 (ja) 1995-11-08

Similar Documents

Publication Publication Date Title
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DE69024744T2 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69123892T2 (de) Behandlung von Katarakt mit prostacyclinverbindungen
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE90565T1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
ATE98127T1 (de) Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SUCAMPO AG, ZUG, CH